A rapid real-time quantitative PCR assay to determine the minimal inhibitory extracellular concentration of antibiotics against an intracellular Francisella tularensis live vaccine strain

Frontiers in Microbiology

Volumn 6, Issue NOV, 2015, Pages

  Aloni Grinstein, Ronit ^a   Shifman, Ohad ^a   Lazar, Shlomi ^a   Steinberger Levy, Ida ^a   Maoz, Sharon ^a   Ber, Raphael ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Antibiogram; Antibiotic susceptibility; Francisella tularensis; Intracellular infection; MIC; MIEC; QPCR; Tularemia

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LIVE VACCINE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CFU COUNTING; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FRANCISELLA TULARENSIS; GENE AMPLIFICATION; GROWTH RATE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOLOCALIZATION; INTRACELLULAR BACTERIUM; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; VERO CELL LINE;

EID: 84949788578     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.01213     Document Type: Article

References (50)

1. Ahmad, S., Hunter, L., Qin, A., Mann, B. J., and van Hoek, M. L. (2010). Azithromycin effectivness against intracellular infections of Francisella. BMC Microbiol. 10:123. doi: 10.1186/1471-2180-10-123
2. Anda, P., Pearson, A. D., and Tarnvik, A. (2007). WHO Guidelines on Tularaemia, ed. A. Tarnvik. Geneva: World Health Organization Epidemic and Pandemic Alert and Response, 21-26.
3. Biswas, S., Raoult, D., and Rolain, J. M. (2008). A bioinformatic approach to understanding antibiotic resistance in intracellular bacteria through whole genome analysis. Int. J. Antimicrob. Agents 32, 207-220. doi: 10.1016/j.ijantimicag.2008.03.017
4. Boisset, S., Caspar, Y., Sutera, V., and Maurin, M. (2014). New therapeutic approaches for treatment of tularemia: a review. Front. Cell. Infect. Microbiol. 4:40. doi: 10.3389/fcimb.2014.00040
5. Bradburne, C. E., Verhoeben, A. B., Manyam, G. C., Chaudhry, S. A., Chang, E. L., Thach, D. C., et al. (2013). Temporal transcriptional response during infection of type II alveolar epithelial cells with Francisella tularensis Live Vaccine Strain (LVS) supports a general host suppression and bacterial uptake by macropinocytosis. J. Biol. Chem. 280, 10780-10791. doi: 10.1074/jbc. M112.362178
6. Carryn, S., Chanteux, H., Seral, C., Mingeot-Leclercq, M. P., Bambeke, F. V., and Tulkens, P. M. (2003). Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North Am. 17, 615-634. doi: 10.1016/S0891-5520(03)00066-7
7. Carryn, S., Van-Bambeke, F., Mingeot-Leclercq, M. P., and Tulkens, P. (2002). Comparative intracellular (THP-1 macrophage) and extracellular activities of β-lactam, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevent concentrations. Antimicrob. Agents Chemother. 46, 2095-2103. doi: 10.1128/AAC.46.7.2095-2103.2002
8. CDC (2013). Tularemia-United States, 2001-2010. MMWR Morb. Mortal. Wkly. Rep. 62, 963-966.
9. Celli, J., and Zahrt, T. C. (2013). Mechanisms of Francisella tularensis intracellular pathogenesis. Cold Spring Harb. Perspect. Med. 3, 1-14. doi: 10.1101/cshperspect.a010314
10. CLSI (1999). Methods for Determining Bactericidal Activity of Antimicrobial Agents: Approved Guidlines. CLSI Document m26-a vol19. Wayne, PA: Clinical and Laboratory Standards Institute.
11. CLSI (2010). Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria: Approved Guidelines-Second Edition. CLSI Document M45-A2. Wayne, PA: Clinical and Laboratory Standards Institute.
12. CLSI (2015). Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fifth Informational Supplement CLSI Document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute.
13. Dennis, D. T., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., et al. (2001). Tularemia as a biological weapon: medical and public health management. JAMA 285, 2763-2773. doi: 10.1001/jama.285.21.2763
14. Easmon, C. S. F., and Crane, J. P. (1985). Uptake of ciprofloxacin by human neutrophils. J. Antimicrob. Chemother. 16, 67-73. doi: 10.1093/jac/16.1.67
15. Eigelsbach, H. T., and Downs, C. M. (1961). Prophylactic effectiveness of live and killed vaccines. 1. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87, 415-425.
16. Ellis, J., Oyston, P. C., Green, M., and Titball, R. W. (2002). Tularemia. Clin. Microbiol. Rev. 15, 631-646. doi: 10.1128/CMR.15.4.631-646.2002
17. Enderlin, G., Morales, L., Jacobs, R. F., and Cross, J. T. (1994). Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin. Infect. Dis. 19, 42-47. doi: 10.1093/clinids/19.1.42
18. Gestin, B., Valade, E., Thibault, F., Schneider, D., and Maurin, M. (2010). Phenotypic and genotypic characterization of macrolide resistance in Francisella tularensis subsp. holarvtica biovar I. J. Antimicrob. Chemother. 65, 2359-2367. doi: 10.1093/jac/dkq315
19. Hall, J. D., Craven, R. R., Fuller, C. J., Pickles, R. J., and Kawula, T. H. (2007). Francisella tularensis replicates within Alveolar Type II epithelial cells in vitro and in vivo following inhalation. Infect. Immun. 75, 1034-1039. doi: 10.1128/IAI.01254-06
20. Horzempa, J., O'Dee, D. M., Shanks, R. M. Q., and Nau, G. (2010). Francisella tularensis pyrF mutants show that replication in nonmacrophages is sufficient for pathogenesis in vivo. Infect. Immun. 78, 2607-2619. doi: 10.1128/IAI.00134-10
21. Johansson, A., Larkeryd, A., Widerstrom, M., Mortberg, S., Myrtannas, K., Ohrman, C., et al. (2014). A respiratory tularemia outbreak caused by diverse clones of Francisella tularensis. Clin. Infect. Dis. 1, 1546-1553. doi: 10.1093/cid/ciu621
22. Jusatz, H. J. (1961). "The geographical disribution of tularemia throughout the world 1911-1959". in World-atlas of Epidemic Diseases, Vol. 3, ed. E. Rodenwaldt (Hamburg: Falk-Verlag), 38.
23. Kaya, A., Deveci, K., Uysal, I. O., Guven, A. S., Demir, M., Uysal, E. B., et al. (2012). Tularemia in children: evaluation of clinical, laboratory and therapeutic features of 27 tularemia cases. Turk. J. Pediatr. 54, 105-112.
24. Keim, P., Johansson, A., and Wagner, D. M. (2007). Molecular epidemlolgy, evolution, and ecology of Francissella. Ann. N. Y. Acad. Sci. 1105, 30-66. doi: 10.1196/annals.1409.011
25. Keren, G., Itzhaki, A., Oron, C., and Keysary, A. (1995). Evaluation of the anti-rickettsial activity of fluoroquinolones. Drugs 49, 208-210. doi: 10.2165/00003495-199500492-00044
26. Keysary, A., Itzhaki, A., Rubinstein, E., Oron, C., and Keren, G. (1996). The in-vitro anti-rickettsial activity of macrolides. J. Antimicrob. Chemother. 38, 727-731. doi: 10.1093/jac/38.4.727
27. Kreizinger, Z., Makrai, L., Helyes, G., Magyar, T., Erdelyi, K., and Gyuranecz, M. (2013). Antimicrobial susceptibility of Francisella tularensis subsp. holarctica strains from Hungry. Central Europe. J. Antimicrob. Chemother. 68, 370-373. doi: 10.1093/jac/dks399
28. Krocova, Z., Hartlova, A., Sokuckova, D., Zivna, L., Kroca, M., Rudolf, E., et al. (2008). Interaction of B cells with intracellular pathogen Francisella tularensis. Microb. Pathog. 45, 79-85. doi: 10.1016/j.micpath.2008.01.010
29. Law, H. T., Sriram, A., Fevang, C., Nix, E. B., Nano, F. E., and Guttman, J. A. (2014). IgIC and PdpA are important for promoting Francisella invasion and intracellular growth in epithelial cells. PLoS ONE 9:e104881. doi: 10.1371/journal.pone.0104881
30. Limaye, A. P., and Hooper, C. J. (1999). Treatment of Tularemia with flurooquinolones: two cases and review. Clin. Infect. Dis. 29, 922-924. doi: 10.1086/520458
31. Lindemann, S. R., McLendon, M. K., Apicella, M. A., and Jones, B. D. (2007). An in vitro model system used to study adherence and invasion of Francisella tularensis live vaccine strain in nonphagocytic cells. Infect. Immun. 75, 3178-3182. doi: 10.1128/IAI.01811-06
32. Ludo, J. S., de Bruin, O. M., Duplantis, B. N., Schmerk, C. L., Chou, A. Y., Elkins, K. L., et al. (2008). The Francisella pathogenicity island protien PdpD is required for full virulence and associates with homologues of the Type VI secretion system. J. Bacteriol. 190, 4584-4595. doi: 10.1128/JB.00198-08
33. Mailles, A., and Vaillant, V. (2014). 10 years of surveillance of human tularemia in France. Euro. Surveill. 19:20956.
34. Maurin, M., Mersali, N. F., and Raoult, D. (2000). Bacterial activities of antibiotics against intracellular Francisella tularensis. Antimicrob. Agents Chemother. 44, 3428-3431. doi: 10.1128/AAC.44.12.3428-3431.2000
35. Maurin, M., and Raoult, D. (1993). "Antibiotic penetration within eukaryotic cells". in Antimicrobial Agents and Intracellular Pathogens, ed. D. Raoult (Boca Raton, FL: CRC Press), 21-37.
36. Moreau, G. B., and Mann, B. J. (2013). Adherence and uptake of Fancisella into host cells. Virulence 4, 826-832. doi: 10.4161/viru.25629
37. Olsufjev, N. G., and Meshcheryakova, I. S. (1983). Subspecific taxonomy of Francisella tularensis McCoy and Chapin 1912. Int. J. Syst. Bacteriol. 33, 872-874. doi: 10.1099/00207713-33-4-872
38. Pankey, G. A., and Sabath, L. D. (2004). Clinical relevance of bacteriostatic versus bactercidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin. Infect. Dis. 38, 864-870. doi: 10.1086/381972
39. Peng, K., Broz, P., Jones, J., Joubert, L. M., and Monack, D. (2011). Elevated AIM2-mediated pyroptosis triggered by hypercytotoxic Francisella mutant strains is attributed to increased intracellular bacteriolysis. Cell Microbiol. 13, 1586-1600. doi: 10.1111/j.1462-5822.2011.01643.x
40. Perez-Castrillon, J. L., Bachiller-Luque, P., Martin-Luquero, M., Mena-Martin, F. J., and Herreros, V. (2001). Tularemia epidemic in Northwerstern Spain: clinical description and therapeutic response. Clin. Infect. Dis. 33, 573-576. doi: 10.1086/322601
41. Qin, A., and Mann, B. J. (2006). Identification of transposon insertion mutants of Francisella tularensis strain Schu S4 deficient in intracellular replication in the hepatic cell line HepG2. BMC Microbiol. 6:69. doi: 10.1186/1471-2180-6-69
42. Staples, J. E. K., Kubota, K. A., Chalcraft, L. G., Mead, P. S., and Peterson, J. M. (2006). Epidemiologic and molecular analysis of human tularemia, United States 1964-2004. Emerg. Infect. Dis. 12, 1113-1118.
43. Sutera, V., Caspar, Y., Boisset, S., and Maurin, M. (2014a). A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis. Front. Cell. Infect. Microbiol. 4:36. doi: 10.3389/fcimb.2014.00036
44. Sutera, V., Levert, M., Burmeister, W. P., Schneider, D., and Maurin, M. (2014b). Evolution towards high-level fluoroquinolone resistance in Francisella species. J. Antimicrob. Chemother. 69, 101-110. doi: 10.1093/jac/dkt321
45. Sutherland, M. D., Goodyear, A. W., Troyer, R. M., Chandler, J. C., Dow, S. W., and Belisle, J. T. (2012). Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Vaccine 30, 4977-4982. doi: 10.1016/j.vaccine.2012.05.037
46. Tarnvik, A., and Chu, M. (2007). New approaches to diagnosis and therapy of tularemia. Ann. N. Y. Acad. Sci. 1105, 378-404. doi: 10.1196/annals.1409.017
47. Tigertt, W. D. (1962). Soviet viable Pasteurella tularensis vaccines: a review of selected articles. Bacteriol. Rev. 26, 354-373.
48. Tulkens, P., and Trouet, A. (1978). The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem. Pharmacol. 27, 415-424.
49. Van-Bambeke, F., Barcia-Macay, M., Lemaire, S., and Tulkens, P. M. (2006). Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Devel. 9, 218-230.
50. Versage, J. L., Severin, D. D., Chu, M. C., and Petersen, J. M. (2003). Development of a multitarget real-time TaqMan PCR assay for enhanced detection of Francisella tularensis in complex specimens. J. Clin. Microbiol. 41, 5492-5499. doi: 10.1128/JCM.41.12.5492-5499.2003